| Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management VP Chavda, P Balar, D Vaghela, HK Solanki, A Vaishnav, V Hala, L Vora Vaccines 11 (1), 160, 2023 | 28 | 2023 |
| Molnupiravir: A versatile prodrug against SARS-CoV-2 variants D Teli, P Balar, K Patel, A Sharma, V Chavda, L Vora Metabolites 13 (2), 309, 2023 | 23 | 2023 |
| Conventional and novel diagnostic tools for the diagnosis of emerging SARS-CoV-2 variants VP Chavda, DD Valu, PK Parikh, N Tiwari, AS Chhipa, S Shukla, SS Patel, ... Vaccines 11 (2), 374, 2023 | 23 | 2023 |
| Advanced phytochemical-based nanocarrier systems for the treatment of breast cancer VP Chavda, LV Nalla, P Balar, R Bezbaruah, V Apostolopoulos, ... Cancers 15 (4), 1023, 2023 | 22 | 2023 |
| Propolis and their active constituents for chronic diseases VP Chavda, AZ Chaudhari, D Teli, P Balar, L Vora Biomedicines 11 (2), 259, 2023 | 18 | 2023 |
| Potential anti-SARS-CoV-2 prodrugs activated by phosphorylation and their role in the aged population VP Chavda, D Teli, PC Balar, D Vaghela, HK Solanki, A Vaishnav, L Vora Molecules 28 (5), 2332, 2023 | 13 | 2023 |
| Nanotheranostics-based management of head and neck cancer VP Chavda, PC Balar, SB Patel Nanotheranostics 7 (2), 202, 2023 | 13 | 2023 |
| Antibody–biopolymer conjugates in oncology: a review VP Chavda, PC Balar, D Teli, M Davidson, J Bojarska, V Apostolopoulos Molecules 28 (6), 2605, 2023 | 12 | 2023 |
| Interventional nanotheranostics in hepatocellular carcinoma VP Chavda, PC Balar, SB Patel Nanotheranostics 7 (2), 128, 2023 | 12 | 2023 |
| Engineered exosomes for cancer theranostics: Next-generation tumor targeting VP Chavda, VV Sugandhi, CV Pardeshi, RJ Patil, M Joshi, BM Patel, ... Journal of Drug Delivery Science and Technology, 104579, 2023 | 8 | 2023 |
| Current status of Cancer Nanotheranostics: Emerging strategies for cancer management VP Chavda, A Khadela, Y Shah, H Postwala, P Balar, L Vora Nanotheranostics 7 (4), 368, 2023 | 7 | 2023 |
| The emergence of hybrid variants of SARS-CoV-2: towards hybrid immunity VP Chavda, S Vuppu, T Mishra, P Balar Vaccines 11 (4), 764, 2023 | 5 | 2023 |
| Phytochemical Loaded Nanovehicles of Biopolymer for Breast Cancer: A Systemic review VP Chavda, S Vuppu, R Bezbaruah, LV Nalla, SNR Gajula, PC Balar, ... Clinical Complementary Medicine and Pharmacology, 100114, 2023 | 4 | 2023 |
| Conjugated Nanoparticles for Solid Tumor Theranostics: Unraveling the Interplay of Known and Unknown Factors VP Chavda, PC Balar, LV Nalla, R Bezbaruah, NR Gogoi, SNR Gajula, ... ACS omega 8 (41), 37654-37684, 2023 | 3 | 2023 |
| Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes V Chavda, KK Zajac, JL Gunn, P Balar, A Khadela, D Vaghela, S Soni, ... Cancer Reports 6, e1821, 2023 | 3 | 2023 |
| Nanocarrier-based delivery of peptides: challenges and way forward VP Chavda, PC Balar, P Dodiya, J Bojarska Nanomedicine 18 (26), 1903-1906, 2023 | 2 | 2023 |
| Parenteral microemulsion for drug delivery: Advances and update VP Chavda, N Gogoi, DA Vaghela, PC Balar, S Daware, DJ Dave Journal of Drug Delivery Science and Technology, 104991, 2023 | 2 | 2023 |
| Protein subunit vaccines: Promising frontiers against COVID-19 VP Chavda, ENHK Ghali, PC Balar, SC Chauhan, N Tiwari, S Shukla, ... Journal of Controlled Release 366, 761-782, 2024 | 1 | 2024 |
| Propolis and Their Active Constituents for Chronic Diseases. Biomedicines 2023, 11, 259 VP Chavda, AZ Chaudhari, D Teli, P Balar, L Vora | 1 | 2023 |
| Oral Vaccine Delivery: Current Status PC Balar, VA Modh, SP Chauhan, HK Solanki, RK Patel, DM Patel, ... Nanocarrier Vaccines: Biopharmaceutics‐Based Fast Track Development, 345-366, 2024 | | 2024 |
Lalitkumar VoraLecturer in Pharmaceutics at Queen's University, UKBestätigte E-Mail-Adresse bei qub.ac.uk
